Detalhe da pesquisa
1.
Comparison of survival for metastatic pancreatic cancer patients treated with CPI-613 versus resected borderline-resectable pancreatic cancer patients.
J Surg Oncol
; 128(5): 844-850, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37341164
2.
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
Invest New Drugs
; 32(5): 937-45, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24916770